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A B S T R A C T   
Screening microbial cultures for specialised metabolites is essential for the discovery of new biologically active 
compounds. A novel, cost-effective and rapid screening method is described for extracting specialised metabolites 
from bacteria grown on agar plates, coupled with HPLC for basic identification of known and potentially novel 
metabolites. The method allows the screening of culture collections to identify optimal production strains and me-
tabolite induction conditions. The protocol was optimised on two Burkholderia species known to produce the anti-
biotics, enacyloxin IIa (B. ambifaria) and gladiolin (B. gladioli), respectively; it was then applied to strains of each 
species to identify high antibiotic producers. B. ambifaria AMMD and B. gladioli BCC0238 produced the highest 
concentrations of the respective antibiotic under the conditions tested. To induce expression of silent biosynthetic 
gene clusters, the addition of low concentrations of antibiotics to growth media was evaluated as known elicitors of 
Burkholderia specialised metabolites. Subinhibitory concentrations of trimethoprim and other clinically therapeutic 
antibiotics were evaluated and screened against a panel of B. gladioli and B. ambifaria. To enhance rapid strain 
screening with more antibiotic elicitors, antimicrobial susceptibility testing discs were included within the induction 
medium. Low concentrations of trimethoprim suppressed the production of specialised metabolites in B. gladioli, 
including the toxins, toxoflavin and bongkrekic acid. However, the addition of trimethoprim significantly improved 
enacylocin IIa concentrations in B. ambifaria AMMD. Rifampicin and ceftazidime significantly improved the yield of 
gladiolin and caryoynencin by B. gladioli BCC0238, respectively, and cepacin increased 2-fold with tobramycin in B. 
ambifaria BCC0191. Potentially novel metabolites were also induced by subinhibitory concentrations of tobramycin 
and chloramphenicol in B. ambifaria. In contrast to previous findings that low concentrations of antibiotic elicit 
Burkholderia metabolite production, we found they acted as both inducers or suppressors dependent on the meta-
bolite and the strains producing them. In conclusion, the screening protocol enabled rapid characterization of 
Burkholderia metabolites, the identification of suitable producer strains, potentially novel natural products and an 
understanding of metabolite regulation in the presence of inducing or suppressing conditions.   
1. Introduction 
Microbial specialised (also known as secondary) metabolites con-
tinue to be a source of new biologically active molecules for use in 
medicine and agriculture (Bérdy 2005; Rutledge and Challis 2015). 
However, their production, extraction and identification from bacterial 
growth medium can be complicated, labour intensive, and time con-
suming. Natural product extraction methods from microbial sources 
frequently involve the use of freeze-drying, evaporation under vacuum, 
adsorption to ion-exchange resins, or use of large volumes of harmful 
solvents (Seidel 2012; Sterner 2012). In addition, the production of 
microbial compounds are frequently influenced by different cultivation 
parameters (e.g. nutrients, light, temperature, pH, and aeration) (Bode 
et al. 2002, Pettit 2011, Begani et al. 2018) and identifying optimum 
growth conditions can require labour intensive screening. This has 
prompted the investigation of alternative approaches to identifying 
novel metabolites, such as high throughput screening (HTS) of synthetic 
compound libraries and fragment-based design (Payne et al. 2006;  
Doak et al. 2016). However, these approaches have had limited success 
due to the nature of the developed assay to screen large numbers of 
compounds. In both cases, inhibition of the target protein by the tested 
compounds is assessed outside the context of the cell, and unfortunately 
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lead compounds are often found to be ineffective in cell-based assays 
(Rutledge and Challis 2015). 
The recent explosion in microbial genome sequencing projects 
(Mukherjee et al. 2017) and ever-increasing computational capacity has 
allowed for the powerful approach of genome mining to be realised. 
Genome sequencing coupled with specific genome mining tools, such as 
antiSMASH (Medema et al. 2011), has revealed that multiple micro-
organisms, beyond the traditionally exploited Streptomyces genus 
(Hopwood 2019) have excellent potential to produce specialised metabo-
lites encoded by biosynthetic gene clusters (BGCs) (Trivella and de Felicio 
2018). Recently, antibiotics and other bioactive molecules have been 
identified in members of the Betaprotebacteria genus Burkholderia (e.g.  
Mahenthiralingam et al. 2011; Ross et al. 2014; Song et al. 2017; Flórez 
et al. 2018; Jenner et al. 2019; Mullins et al. 2019; Jones et al. 2020). Novel 
gene clusters identified by genome mining also demonstrate that Bur-
kholderia carry multiple silent or cryptic biosynthetic loci with untapped 
metabolite potential (Depoorter et al. 2016; Kunakom and Eustáquio 2019;  
Mullins et al. 2020). However, despite the identification of novel BGCs, 
activating these silent gene clusters continues to present a major challenge. 
The addition of induction molecules or chemical elicitors to growth 
media, such as glycerol has been used routinely for metabolite in-
vestigations with Burkholderia species (Keum et al. 2009;  
Mahenthiralingam et al. 2011; Song et al. 2017; Mullins et al. 2019). 
Subinhibitory concentrations of clinically used antibiotics (e.g. tri-
methoprim and piperacillin); (Seyedsayamdost 2014), have also been 
shown to induce specialised metabolites in Burkholderia thailandensis. 
Systematic investigation into elicitors that awaken silent BGCs would 
have a major impact on drug discovery (Begani et al. 2018). Therefore, 
a rapid screening method to aid compound identification and obtain 
optimal producer strains, as well as allow the user to determine con-
ditions needed to express these novel compounds, is urgently required 
to unlock the genetic potential of Burkholderia and other antibiotic 
producing microorganisms. 
Here we describe a novel, highly efficient screening method based on 
solvent extraction of specialised metabolites directly from agar plate cul-
tures, coupled with reversed-phase high-performance liquid chromato-
graphy (HPLC) as a basic and widely available compound profiling ana-
lysis. We expanded the protocol to incorporate antibiotic susceptibility 
testing discs in the agar, and rapidly screen large panels of Burkholderia 
strains for novel metabolite induction or suppression properties caused by 
these gene expression altering antimicrobials. The method allowed the 
identification of known and novel compounds, screening novel chemical 
elicitors, and identification of optimal production strains and growth/ 
metabolite induction conditions. In this study we evaluated Burkholderia as 
specialised metabolite producers, but the method could readily be em-
ployed for other bacteria which demonstrate similar growth properties to 
these rapidly growing Gram-negative bacteria. 
2. Materials and methods 
2.1. Bacterial strains and growth conditions 
All strains of Burkholderia (Table 1) were drawn from the Cardiff 
University Burkholderia culture collection (Mahenthiralingam et al. 
2011; Mullins et al. 2020) and other recognised strain repositories (The 
Belgium Co-ordinated Collections of Microorganisms/Laboratory of 
Microbiology, Ghent [BCCM/LMG]; The Burkholderia cepacia Research 
Laboratory and Repository [BcRLR]), and stored at −80 °C in Tryptone 
Soya Broth (TSB; Oxoid) containing 8% (v/v) dimethylsulfoxide 
(DMSO; Sigma). Cultures were revived onto Tryptone Soya Agar (TSA; 
Oxoid) in Petri dishes and incubated at 30 °C for 24 h. All cultures were 
routinely streaked to single colonies on TSA to check for purity. Over-
night liquid cultures were prepared by inoculating 5 ml of TSB with 
confluent growth from a fresh TSA plate, incubated at 30 °C on a 
rocking platform (150 rpm) and used as bacterial inoculum of agar 
medium for specialised metabolite induction. 
2.2. Rapid screening method for the detection of specialised metabolites 
For specialised metabolite induction, bacterial inoculum was 
streaked (from a fresh overnight liquid culture; Fig. 1A) using a sterile 
swab (Fisher Scientific UK Ltd.) onto solidified (purified agar; Oxoid) 
basal salts medium (Hareland et al. 1975) consisting of (g l−1) 
K2HPO4.3H2O (4.25), NaH2PO4.H2O, (1.0), NH4Cl (2.0), MgSO4.7H2O 
(0.2), FeSO4.7H2O (0.012), MnSO4.H2O (0.003), ZnSO4.7H2O (0.003), 
CoSO4.7H2O (0.001), nitrilotriacetic acid trisodium salt (0.1), casamino 
acid (0.5), yeast extract (0.5) and supplemented with 4 g l−1 glycerol 
(BSMG; Mahenthiralingam et al. 2011). To ensure reproducibility, all 
BSMG plates contained 20 ml media and each plate was streaked 10 
times (Fig. 1A) with one swab of bacteria. After incubation at 30 °C for 
72 h, the microbial biomass was removed from the agar plate using a 
sterile cell scraper (Fisher Scientific UK Ltd) and a 20 mm agar disc cut 
from the metabolite-induced plate and then placed into a 30-ml wide- 
mouth amber glass bottle (to reduce exposure to light) with 0.5 ml 
dichloromethane (see Fig. S1). Acetonitrile and ethylacetate were also 
evaluated as solvents but were not used for follow up experiments as 
dichloromethane proved optimal (see Section 3). Metabolites were ex-
tracted by incubating for up to 3 h at room temperature (approximately 
22 °C) on a rocking platform shaker (40 rpm). The solvent extract was 
carefully transferred from the bottle using a glass Pasteur pipette to 
avoid agar carry-over, centrifuged at 14,000 ×g and placed into 2.0 ml 
amber glass vials for reversed-phase HPLC analysis. 
2.3. HPLC analysis 
Extracts (20 μl injection volume) were analysed on a Waters® 
AutoPurification™ High Performance Liquid Chromatography (HPLC) System 
fitted with a reversed-phase analytical column (Waters® XSelect CSH C18, 
4.6 × 100 mm, 5 μm) and a C18 SecurityGuard™ cartridge (Phenomenex) in 
series. Detection of compounds was by absorbance at 210–400 by a photo- 
diode array detector (PDA). Mobile phases consisted of (A) water with 0.1% 
formic acid and (B) acetonitrile with 0.1% formic acid with a flow rate of 
1.5 ml min−1. Elution conditions were as follows: 0 to 1 min, 95% phase A/ 
5% phase B; 1 to 9 min, gradient of phase A from 95 to 5% and gradient of 
phase B from 5% to 95%; 10 to 11 min, 5% phase A/95% phase B; 11 to 
15 min, 95% phase A/5% phase B. Known specialised metabolites were 
identified by HPLC peak retention times and UV absorbance characteristics, 
and by referencing these to internal standards characterised by High 
Resolution Liquid Chromatography-Mass Spectrometry (LC-MS) and Nuclear 
Magnetic Resonance (NMR) as described (Mahenthiralingam et al. 2011;  
Song et al. 2017; Mullins et al. 2019; Jones et al. 2020). 
Metabolite peak heights were calculated using MassLynx V4.1 
software (www.waters.com) and differences in mean peak areas with 
treatment were determined by analysis of variance (ANOVA) with the 
least significant difference (LSD) test at α = 0.05 implemented in IBM 
SPSS Statistics v25. Additional statistics were done using a two-tailed t- 
test. Purified pyrrolnitrin (Sigma) was used as a standard to confirm 
HPLC detection and peak retention time of this specialised metabolite. 
2.4. Metabolite induction and suppression assay with antibiotics 
To investigate the use of trimethoprim as a gene expression elicitor of 
silent BGCs, the above rapid screening method for the detection of spe-
cialised metabolites was employed. BSMG agar was supplemented with 
low concentrations of trimethoprim (0, 0.5, 1.0, 2.0, 5.0, 10.0 μg ml−1), 
and inoculated with four strains of Burkholderia gladioli (BCC1665, 
BCC1678, BCC1686, BCC1701) in triplicate. All inoculated plates were 
incubated at 30 °C for 72 h and analysed by HPLC as described above. 
For more rapid analysis, antimicrobial susceptibility testing (AST) 
discs (Oxoid) were placed into BSMG plates. Trimethoprim, rifampicin, 
chloramphenicol, minocycline, levofloxacin, tobramycin, ceftazidime, 
amikacin, and meropenem were examined as clinically relevant anti-
biotics (see Table 2 for the concentrations used). Essentially, molten 
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BSMG agar was cooled to 50 °C and two AST discs were equally spaced in 
a 9 cm plastic Petri-dish prior to plate pouring and then adjusted so that 
they were beneath the agar using sterile forceps before the agar set. 
Antibiotic plates were streaked with two B. ambifaria (AMMD, BCC0191) 
and two B. gladioli strains (BCC0238, BCC1697) in duplicate, incubated 
at 30 °C for 72 h. A 20 mm disc was cut from the agar above the AST disc 
and placed into a 30-ml wide-mouth amber glass bottle with 0.5 ml di-
chloromethane and analysed for specialised metabolites as above. 
3. Results and discussion 
3.1. Optimization of the rapid screening method 
Optimization of the rapid screening method was carried out using 
Burkholderia species identified as producers of the bioactive polyketides, 
enacyloxin IIa (Mahenthiralingam et al. 2011) and gladiolin (Song et al. 
2017), from Burkholderia ambifaria strain AMMD and B. gladioli strain 
BCC0238, respectively. After growth of the bacteria for 72 h and removal 
of biomass, initial experiments evaluated the use of different volumes of 
extraction solvent (5, 2, 1, 0.5 ml) and injection volumes for HPLC 
analysis (2, 5, 10, 15, 20 μl); dichloromethane was used as the initial 
solvent to optimise the method, with acetonitrile and ethylacetate eval-
uated subsequently. It was observed that consistent and reproducible 
HPLC detection of enacyloxin IIa and gladiolin was obtained from 20 mm 
agar discs extracted with 0.5 ml dichloromethane and 20 μl sample in-
jection volumes (Fig. 1B). After initial detection of compounds by HPLC 
and subsequent confirmation of peak identity by referencing to known 
standards confirmed by LC-MS (Mahenthiralingam et al. 2011; Song 
et al. 2017; Mullins et al. 2019; Jones et al. 2020), shorter solvent in-
cubation times were investigated as a means to increase rapidity of the 
method with maximum extraction efficiency. Results showed that after 
2 h incubation of the metabolite-induced agar disc in dichloromethane 
significantly higher (n = 3) levels of both enacyloxin IIa (p = 0.016) and 
gladiolin (p = 0.003) were detected than at 1 h, with no further increase 
after 3 h incubation (Fig. 1C). In addition, the azapteridine antibiotic, 
toxoflavin a known phytotoxin (Furuya et al. 1997; Lee et al. 2016) and 
antifungal (Li et al. 2019) compound produced by B. gladioli was also 
readily identified; toxoflavin significantly (n = 3, p = 0.001) increased 
in concentration with solvent incubation time up to 2 h (Fig. 1C). This 
extraction optimisation demonstrated that a range of known Burkholderia 
metabolites could be readily characterised using this rapid screening 
method. Acetonitrile and ethylacetate were also tested as extraction 
solvents, with HPLC analysis showing that all three metabolites (en-
acyloxin IIa, gladiolin and toxoflavin) could be easily detected in ex-
tracts, but at lower concentrations than with dichloromethane (data not 
shown). This clearly demonstrated that the rapid screening method can 
be easily modified for use with different solvents to allow extraction of 
other specialised metabolites dependent on their chemical characteristics 
and solubility in different solvents. 
The use of reversed-phase HPLC in gradient mode is a technique 
widely used to evaluate compound diversity in organic solvent extracts 
of microbial specialised metabolites grown in liquid media (e.g. Higgs 
et al. 2001; Tormo et al. 2003; Rutledge and Challis 2015). However, its 
use directly from extracts from solid media is less frequent. The direct 
Table 1 
Burkholderia species strains used in this study.       
Strain name Alternative strain name 
(s) 
Source details Specialised metabolites known to be produced References  
Burkholderia ambifaria 
AMMD LMG 19182T, ATCC 
BAA-244T 
Pea rhizosphere, USA Enacyloxin, pyrrolnitrin, burkholdines, AFC- 
BC11, hydroxyquinolines 
Coenye et al. (2001); Mahenthiralingam et al. 
(2011); Mullins et al. (2019) 
BCC0118 CEP0617, 
R-9917 
CF patient sputum, USA Enacyloxin, pyrrolnitrin, burkholdines, AFC- 
BC11, hydroxyquinolines 




Soil, USA (biocontrol strain) Cepacin, pyrrolnitrin burkholdines, phenazine Mao et al. (1997); Mullins et al. (2019) 
BCC0203 Bc-F, 
HG1-A 
Maize rhizosphere, USA 
(biocontrol strain) 
Enacyloxin, pyrrolnitrin, burkholdines, 
bactobolins, AFC-BC11 
Mao et al. (1998); Mullins et al. (2019) 
BCC0207 AMMDT, 
LMG 19182T 
AMMDT stock Enacyloxin, pyrrolnitrin, burkholdines, AFC- 
BC11, hydroxyquinolines 
Mullins et al. (2019) 
BCC0250 CEP0958, 
R-9927 
CF patient sputum, Australia Enacyloxin, pyrrolnitrin, burkholdines, AFC- 
BC11, hydroxyquinolines 
Coenye et al. (2001); Mullins et al. (2019) 
BCC0480 HI2427 Soil, USA Enacyloxin, pyrrolnitrin, burkholdines, AFC- 
BC11, hydroxyquinolines 
Mullins et al. (2019) 
BCC1248 KW0-1 Maize rhizosphere, USA Enacyloxin, pyrrolnitrin, burkholdines, AFC- 
BC11, phenazine 
Ramette and Tiedje (2007); Mullins et al. (2019) 
Burkholderia gladioli 
BCC0238 MA4 CF patient sputum, USA Toxoflavin, gladiolin, caryoynencin, icosalides Song et al. (2017); Jenner et al. (2019); Jones et al. 
(2020) 
BCC0771 LMG 2216T, 
ATCC 10248T, DSM 
4285T 
Gladiolus sp. bulb, USA Toxoflavin, gladiolin, caryoynencin, icosalides Coenye et al. (1999); Jones et al. (2020) 
BCC1622 AU17110 CF patient sputum, USA Toxoflavin, gladiolin, caryoynencin, icosalides Jones et al. (2020) 
BCC1647 LMG 6882 Gladiolus sp. bulb, USA Toxoflavin, gladiolin, caryoynencin, icosalides Coenye et al. (1999); Jones et al. (2020) 
BCC1665 AU19515 CF patient sputum, USA Toxoflavin, enacyloxin, caryoynencin, 
icosalides, bongkrekic acid 
Jones et al. (2020) 
BCC1686 AU16339 CF patient sputum, USA Toxoflavin, enacyloxin, caryoynencin, 
icosalides, bongkrekic acid 
Jones et al. (2020) 
BCC1678 AU14817 CF patient sputum, USA Toxoflavin, enacyloxin, icosalides, bongkrekic 
acid, sinapigladiosidea 
Jones et al. (2020) 
BCC1697 AU18435 CF patient sputum, USA Toxoflavin, icosalides, bongkrekic acid Jones et al. (2020) 
BCC1701 AU19655 CF patient sputum, USA Toxoflavin, enacyloxin, caryoynencin, 
icosalides, bongkrekic acid 
Jones et al. (2020) 
BCC1721 AU22444 CF patient sputum, USA Toxoflavin, gladiolin, caryoynencin, icosalides Jones et al. (2020) 
BCC1806 AU14276 CF patient sputum, USA Toxoflavin, gladiolin, caryoynencin, icosalides Jones et al. (2020) 
BCC1811 AU22765 CF patient sputum, USA Toxoflavin, gladiolin, caryoynencin, icosalides Jones et al. (2020) 
a No biosynthetic gene cluster for sinapigladioside has been identified (Flórez et al. 2018) but the compound has been identified by HPLC detection (Jones et al. 2020).  
G. Webster, et al.   Journal of Microbiological Methods 178 (2020) 106057
3
analysis of samples from standardised agar plates increased the high 
throughput nature of the protocol allowing for greater sample replica-
tion and reproducibility, and the investigation of multiple growth 
conditions. It also modelled biofilm and high-density surface growth 
conditions which are preferred by multiple bacteria and known to 
activate regulatory systems such as quorum sensing, essential for ex-
pression of certain antibiotics (e.g. enacyloxin IIa; Mahenthiralingam 
et al. 2011). In addition, the method also allows rapid screening and 
identification of new strains that naturally produce higher levels of 
desired compounds (see below). Downstream of HPLC, genetic 
Fig. 1. The detection of Burkholderia metabolites by HPLC and optimisation of solvent extraction time. (A) An example of bacterial growth (B. gladioli BCC0238) 
streaked on a 9.0 cm diameter BSMG agar plate for metabolite extraction grown at 30 °C for 72 h. (B) HPLC profiles of enacyloxin IIa produced by B. ambifaria AMMD 
(top panel) and gladiolin and toxoflavin produced by B. gladioli BCC0238 (bottom panel). (C) Increase in enacyloxin IIa extraction with time using dichloromethane 
from B. ambifaria AMMD. (D, E) Increase in gladiolin and toxoflavin extraction with time using dichloromethane from B. gladioli BCC0238. Means followed by the 
same letter are not significantly different according to the least significant difference test at p  <  0.05 (n = 3): (C) LSD = 9.70E+06 AU, (D) LSD = 1.67E+06 AU, 
(E) LSD = 1.38E+06 AU. AU = absorbance units measured at 210–400 nm. 
Table 2 
List of antimicrobial susceptibility testing (AST) discs used as metabolite inducers/suppressors in this study.       
AST disc Concentration (μg) Disc abbreviation Antibiotic class Mechanism  
Amikacin 30 AK30 Aminoglycoside Protein synthesis inhibitor 
Tobramycin 10 TOB10 Aminoglycoside Protein synthesis inhibitor 
Chloramphenicol 10 C10 Chloramphenicol Protein synthesis inhibitor 
Minocycline 30 MH30 Tetracycline Protein synthesis inhibitor 
Levofloxacin 1 LEV1 Fluoroquinolone DNA synthesis inhibitor 
Rifampicin 2 RD2 Ansamycin RNA synthesis inhibitor 
Ceftazidime 10 CAZ10 Cephalosporins Cell wall synthesis inhibitor 
Meropenem 10 MEM10 Carbapenem Cell wall synthesis inhibitor 
Trimethoprim 1.25 W1.25 DHFR inhibitor Folic Acid synthesis inhibitor 
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engineering can aid compound identification by comparative metabo-
lite analysis of gene knockout mutants and wild-type strains (Kunakom 
and Eustáquio 2019). For example, cepacin and its related HPLC peak 
was determined in B. ambifaria BCC0191 after the BGC encoding ce-
pacin was disrupted through insertional mutagenesis (Mullins et al. 
2019). Similarly, the use of known standard compounds analysed 
alongside metabolite extracts can also help identify unknown peaks. In 
the current study purified pyrrolnitrin was used to help identify this 
compound in extracts from B. ambifaria (see below). Ultimately, further 
analyses beyond HPLC such as mass identification by LC-MS or struc-
ture elucidation by NMR are required for accurate compound identifi-
cation (Mahenthiralingam et al. 2011; Song et al. 2017). However, for 
initial metabolite profiling, optimisation of extraction conditions and 
identifying production strains, the protocol proved very useful. 
3.2. Identification of suitable production strains of specialised metabolites 
To identify high production strains for both enacyloxin IIa and 
gladiolin and facilitate large-scale purification of Burkholderia meta-
bolites in sufficient quantities for future toxicity and efficacy testing, a 
panel of seven B. ambifaria and seven B. gladioli strains were screened 
using the rapid screening method. Results showed that strains B. am-
bifaria AMMD and B. gladioli BCC0238 were the optimum strains for the 
induction and production of enacyloxin IIa and gladiolin, respectively 
under the conditions tested. For both strains, significantly higher con-
centrations of antibiotics (n = 3; p  <  0.01) were observed when 
compared with six other strains of the same species. Interestingly, the 
amounts of gladiolin produced by all B. gladioli strains evaluated were 
highly variable (Fig. 2), whereas enacyloxin IIa production was more 
consistent among the B. ambifaria strains tested, with the exceptions of 
AMMD (high concentration) and BCC1248 (low concentration). Two of 
the B. ambifaria isolates evaluated, BCC0207 and AMMD, were derived 
from the same original stock and are both representative of the B. 
ambifaria type strain AMMD. However, the strain designated AMMD in 
this study has been used routinely over a period of time to investigate 
enacyloxin IIa (Mahenthiralingam et al. 2011; Masschelein et al. 2019), 
and this may have inadvertently resulted in the selection of an im-
proved strain with an altered genotype (Bunch and Harris 1986) for 
enacyloxin IIa production. Utilising strains that naturally produce high 
concentrations of specialised metabolites when available is preferential 
over engineering native hosts to improve metabolite production or 
heterologously expressing biosynthetic genes in other hosts, especially 
for recently identified, uncharacterised or large BGCs (Zhang et al. 
2016). Natural efficient high metabolite producers are already 
equipped with the necessary cellular factors to produce the compound 
of interest, including those needed for precursor and product bio-
synthesis, pathway regulation, self-resistance and transport. Bur-
kholderia strains shown to produce high concentrations of gladiolin and 
enacyloxin IIa identified during this study were subsequently used to 
enable the purification of sufficient antibiotic to investigate their ac-
tivity on a panel of multi-drug resistant strains of urogenital pathogens, 
Neisseria gonorrhoeae and Ureaplasma spp. (Heath et al. 2020). 
3.3. Effect of trimethoprim on specialised metabolites of B. gladioli 
Previously, exposure to trimethoprim at subinhibitory concentra-
tions has been reported as a global activator for Burkholderia thai-
landensis specialised metabolites, able to induce previously un-
characterised BGCs (Seyedsayamdost 2014; Okada et al. 2016; Li et al. 
2020). To evaluate the trimethoprim induction phenomenon on dif-
ferent Burkholderia species, four strains of B. gladioli (BCC1665, 
BCC1678, BCC1686 and BCC1701) were grown on BSMG agar plates 
with a range of trimethoprim concentrations (0–10 μg ml−1) and me-
tabolites were analysed as above. Initial experiments showed that the 
minimum inhibitory concentration (MIC) of trimethoprim for a number 
of strains of B. gladioli grown on BSMG agar plates (Table S1) or in TSB 
(Fig. S2) was between 2 and 10 μg ml−1. 
In the presence of trimethoprim only known B. gladioli metabolites 
were detected by HPLC (toxoflavin, enacyloxin IIa, caryoynencin, 
bongkrekic acid and sinapigladioside) and quantified (Fig. 3), with no 
evidence of novel metabolites being detected. It was observed that in-
stead of induction, trimethoprim was generally having a suppressive 
effect on the known B. gladioli metabolites, including the respiratory 
toxin bongkrekic acid (Anwar et al. 2017). All B. gladioli strains, except 
for strain BCC1665, showed a dramatic reduction in metabolite pro-
duction at all trimethoprim concentrations analysed, including sub-
inhibitory concentrations 0.5–1.0 μg ml−1 in a clear concentration- 
dependent manner (Fig. 3). Only B. gladioli BCC1665, showed some 
stimulation in the production of caryoynencin, but had similar levels of 
enacyloxin IIa and bongkrekic acid, and a decline in toxoflavin, when 
compared to the control without trimethoprim at concentrations be-
tween 0.5 and 2.0 μg ml−1. Closer examination of the data shows that 
three (BCC1678, BCC1686 and BCC1701) out of the four B. gladioli 
strains tested had a statistically significant reduction in bongkrekic acid 
production when exposed to subinhibitory concentrations of 1 μg ml−1 
of trimethoprim (see Fig. S3, data from BCC1686 shown as an example). 
Interestingly, the suppression of Burkholderia metabolites by the ad-
dition of subinhibitory concentrations of trimethoprim may have an 
unexpected benefit when used in a clinical setting. Cystic fibrosis (CF) 
patients often have polymicrobial infections of the lungs which can in-
clude members of the Burkholderia cepacia complex, strains of B. gladioli, 
and other bacteria (LiPuma 2010). For this reason, they are prescribed a 
cocktail of antibiotics including trimethoprim (Avgeri et al. 2009). The 
potential suppression of toxic metabolites like bongkrekic acid and tox-
oflavin by trimethoprim in CF patients with known B. gladioli infections 
would be clearly valuable. If toxins were produced by B. gladioli in the 
lung this would impose a further risk factor to CF patients. Previously, B. 
gladioli infections have been associated with severe symptoms caused by 
systemic infection including hypertrophic pulmonary osteoarthropathy 
(Jones et al. 2001) and death (Khan et al. 1996), although this has not 
been attributed to these toxic metabolites. Recently, the need to define B. 
gladioli strains which encode the bongkrekic acid gene cluster from 
strains that do not because of its link with food-poisoning (Jiao et al. 
2013) has led to the reassessment of the species using phylogenomic 
approaches (Jones et al. 2020). All strains that were bongkrekic acid BGC 
positive, including CF patient isolates all clustered in one major group, 
and were referred to as B. gladioli Group 1 (Jones et al. 2020). 
3.4. Effect of low concentrations of other antibiotics on Burkholderia 
specialised metabolites 
Since trimethoprim was observed to have a clear suppressive effect 
on B. gladioli metabolite production and yet other antibiotics are known 
to stimulate natural product biosynthesis in other Burkholderia 
(Seyedsayamdost 2014), it was decided to test a range of different an-
tibiotics on a panel of other Burkholderia species and screen their me-
tabolite profiles using HPLC. To allow for more rapid screening, com-
mercially available antimicrobial susceptibility testing (AST) discs 
impregnated with standardised concentrations of antibiotic were tested 
(Table 2). Preliminary experiments comparing the effect of trimetho-
prim within the agar (1.0 μg ml−1) against trimethoprim diffusing out 
from an AST disc (1.25 μg disc−1) was undertaken in order to de-
termine the feasibility of the method (Fig. S3). Results showed that 
there was no significant difference between the effect of trimethoprim 
AST discs on bongkrekic acid production by B. gladioli BCC1686 when 
compared to a similar concentration of trimethoprim added directly to 
the growth media. Both treatments significantly (n = 4; p  <  0.01) 
suppressed the metabolite, bongkrekic acid when compared to the 
control without trimethoprim. 
Two B. gladioli (BCC0238, BCC1697) and two B. ambifaria (AMMD, 
BCC0191) strains were screened for changes in their specialised metabo-
lites against a panel of 9 different antibiotics (covering 8 different 
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antibiotic classes and 5 mechanisms of action; Table 2). Since the con-
centration of antibiotics used for the AST discs were determined by the 
manufacturer, analysis of the growth and inhibition of the bacteria was 
first assessed. All four strains of Burkholderia were inhibited by minocy-
cline and meropenem, and both strains of B. gladioli additionally showed 
clear inhibition zones by the aminoglycosides, tobramycin and amikacin 
(Table S2 and Fig. S4). Both meropenem and minocycline are used to treat 
Burkholderia infections in addition to trimethoprim (Avgeri et al. 2009). 
MIC values reported for non-CF patient isolates of Burkholderia cepacia 
complex (Bcc) bacteria and clinical isolates of B. gladioli for both mino-
cycline and meropenem are in the range 1–8 μg ml−1 (Zhou et al. 2007;  
Mazer et al. 2017), suggesting that the B. ambifaria and B. gladioli isolates 
used here would be inhibited by these antibiotics at the concentration 
employed. In addition, a study of clinical isolates of B. gladioli report that 
they are naturally susceptible to aminoglycosides (Segonds et al. 2009), 
whereas members of the Bcc (which includes B. ambifaria) are intrinsically 
resistant to this class of antibiotics (Nzula et al. 2002). 
However, despite the inhibition of growth by certain antibiotics, all 
nine antibiotics and four Burkholderia strain combinations were analysed 
by the rapid screening method. All the Burkholderia strains showed a 
differing response in terms of their metabolite profile to the panel of 
antibiotics tested (Figs. 4 and 5; Figs. S5 and S6). The majority of strain- 
antibiotic treatment combinations resulted in a significant reduction in 
metabolite production or had no significant increase (Figs. 4 and 5; Figs. 
Fig. 2. Screening and identification of high antibiotic production strains of B. ambifaria for enacyloxin IIa and B. gladioli for gladiolin. (A) enacyloxin IIa from B. 
ambifaria and (B) gladiolin from B. gladioli strains. All strains tested were grown on BSMG for 72 h at 30 °C. Means followed by the same letter are not significantly 
different according to the least significant difference test at p  <  0.05 (n = 3): (A) LSD = 9.72E+06 AU, (B) LSD = 8.74E+05 AU. AU = absorbance units measured 
at 210–400 nm. 
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S5 and S6). Certain interactions resulted in significant increases in 
known metabolite production or caused the induction of unidentified 
and potentially novel metabolites. For example, a significant increase 
(n = 4; p  <  0.001) in both the phytotoxin, toxoflavin and the antibiotic, 
gladiolin were observed for B. gladioli BCC0238 in the presence of 2 μg 
rifampicin (Fig. 4). In an analogous fashion, the polyyne, caryoynencin 
produced by B. gladioli BCC0238 was significantly increased (n = 4; 
p  <  0.001) in the presence of 10 μg ceftazidime. 
A similar stimulatory effect of rifampicin was seen with B. ambifaria 
strain BCC0191 (Fig. 5) with an increase (n = 4; p = 0.003) in the 
production of the anti-oomycete polyyne compound, cepacin (Mullins 
et al. 2019). A significant increase (approx. 2-fold) in the stimulation of 
cepacin production above levels induced by the control and that by 
rifampicin was observed by 10 μg tobramycin (n = 4; p  <  0.001). 
Interestingly, tobramycin also stimulated a 5-fold increase (n = 4; 
p  <  0.001) in the production of an unidentified metabolite peak (HPLC 
peak retention = 7.2 mins; UV absorbance = 301 nm) by B. ambifaria 
BCC0191. Other significant increases in metabolites included that of: B. 
ambifaria AMMD antibiotic enacyloxin IIa by trimethoprim; an increase 
in pyrrolnitrin by chloramphenicol; induction of an unidentified me-
tabolite peak (HPLC peak retention = 6.89 mins; UV absor-
bance = 330 nm) by chloramphenicol (Fig. S5). AntiSMASH analysis of 
the genomes from the two strains of B. ambifaria with novel metabolite 
peaks detected revealed them to have several uncharacterised BGCs 
including nonribosomal peptide synthetase (NRPS), polyketide syn-
thase PKS and NRPS-type 1 PKS hybrid gene clusters (Mullins et al. 
2019). Further investigation is needed to identify if the expression of 
any of these BGCs is activated by the presence of stimulatory antibiotics 
and if the novel metabolite peaks correspond to the specialised meta-
bolite biosynthesis they encode. 
Subinhibitory concentrations of antibiotics have long been known to 
have multiple effects on bacterial cells (Davies et al. 2006), but it is only 
recently with the advent of genome transcription analyses that these 
activities can been studied in detail. Low doses of rifampicin and ery-
thromycin have been shown to change the expression of up to 5% of the 
transcripts in Salmonella enterica, with many of them being upregulated 
(Goh et al. 2002). Similarly, the addition of subinhibitory concentra-
tions of trimethoprim to B. thailandensis resulted in both transcriptional 
and translational alterations, with 8.5% of the transcriptome and 5% of 
the proteome up or downregulated by more than 4-fold (Li et al. 2020). 
It was proposed that the low concentrations of trimethoprim inhibit 
one‑carbon metabolic processes, which leads to an accumulation of 
homoserine, that subsequently induces silent BGCs by a LuxR-type 
transcriptional regulator (Li et al. 2020). Understanding the mechan-
isms of antibiotic-based induction and/or suppression of B. gladioli and 
B. ambifaria metabolites seen in the current study would be interesting 
to address by global transcriptomic analysis. However, in the interim 
subinhibitory concentrations of antibiotics can clearly be used to dis-
cover specialised metabolites, improve the levels of specialised meta-
bolites for further investigation, and to understand clinically if the 
presence of certain antibiotics drive detrimental toxin production in 
Burkholderia. 
Fig. 3. Effect of different concentrations of trimethoprim (0–10 μg ml−1) on the metabolite profile of different Burkholderia gladioli strains. (A) Strain BCC1665 (B) Strain 
BCC1686 (C) BCC1701 (D) BCC1678. Metabolites evaluated were toxoflavin, enacyloxin IIa, caryoynencin, bongkrekic acid and sinapigladioside (n = 9). The mean 
metabolite peak height (plus or minus the standard deviation of the mean) is plotted for each B. gladioli strain. AU = absorbance units measured at 210–400 nm. 
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4. Summary 
Here we have reported the use of a relatively simple, cost effective 
screening procedure for the investigation and optimisation of bacterial 
specialised metabolites. In this study we have been able to readily screen 
multiple strains of B. gladioli and B. ambifaria using a range of growth 
conditions and evaluating different elicitor molecules. A screening method 
that can provide rapid and reproducible profiles of specialised metabolites 
from Burkholderia species and other bacteria is a useful tool that can be 
utilised in research-based discovery of new antibiotics and other 
biotechnologically relevant metabolites. The method can be readily mod-
ified to investigate different induction conditions including, temperature, 
incubation time, media pH, carbon source and alternative metabolite in-
ducers. Further understanding of how novel inducers or suppressors, such as 
low concentrations of antibiotics, act on bacterial specialised metabolite 
production has both medical and agricultural implications. Reducing ex-
pression of toxins from Burkholderia would benefit people with Burkholderia 
respiratory infections, such as those with cystic fibrosis, while activating the 
production of antimicrobial metabolites has important implications for 
natural product discovery and use of biopesticides in agriculture. 
Fig. 4. Effect of different antibiotics within AST discs on the metabolite production of Burkholderia gladioli BCC0238. Nine different antibiotics were screened as 
shown by the key on the right. The effect on the following metabolites was evaluated as shown in each panel: (A) toxoflavin (B) gladiolin and (C) caryoynencin 
production after 72 h at 30 °C. Antibiotic concentrations of AST discs are described in Table 2. Means followed by the same letter are not significantly different 
according to the least significant difference test at p  <  0.05 (n = 4): (A) LSD = 4.46E+06 AU, (B) LSD = 2.80E+06 AU, (C) LSD = 7.70E+05 AU. Asterisks denote 
antibiotics that were inhibitory to BCC0238 growth. AU = absorbance units measured at 210–400 nm. 
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